Background: The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection. Methods: Patients with stage IIIB-IV NSCLC receiving nivolumab at Sant'Andrea Hospital and Regina Elena National Cancer Institute from June 2016 to July 2017 were enrolled onto this study. Major clinicopathological parameters were retrieved and correlated with patients' survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision making process. Results: A total of 102 patients were included in this study. The median age was 69 years (range 44-85 years), 69 (68%) were male and 52% had ECOG PS 0. Loco-regional/distant lymph nodes were the most commonly involved site of metastasis (71%), followed by lung parenchyma (67%) and bone (26%). Overall survival (OS) in the whole patients' population was 83.6%, 63.2% and 46.9% at 3, 6 and 12 months, respectively; while progression-free survival (PFS) was 66.5%, 44.4% and 26.4% at 3, 6 and 12 months, respectively. At univariate analysis, age ≥ 69 years (P = 0.057), ECOG PS (P < 0.001), the presence of liver (P < 0.001), lung (P = 0.017) metastases, lymph nodes only involvement (P = 0.0145) were significantly associated with OS and ECOG PS (P < 0.001) and liver metastases (P < 0.001), retained statistical significance at multivariate analysis. A prognostic nomogram based on three variables (liver and lung metastases and ECOG PS) was built to assign survival probability at 3, 6, and 12 months after nivolumab treatment commencement. Conclusion: We developed a nomogram based on easily available and inexpensive clinical factors showing a good performance in predicting individual OS probability among NSCLC patients treated with nivolumab. This prognostic device could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enrollment onto clinical trials.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab / Botticelli, A.; Salati, M.; Di Pietro, F. R.; Strigari, L.; Cerbelli, B.; Zizzari, I. G.; Giusti, R.; Mazzotta, M.; Mazzuca, F.; Roberto, M.; Vici, P.; Pizzuti, L.; Nuti, M.; Marchetti, P.. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 17:1(2019), p. 99. [10.1186/s12967-019-1847-x]

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Botticelli A.;Di Pietro F. R.;Strigari L.;Cerbelli B.;Zizzari I. G.;Giusti R.;Mazzotta M.;Mazzuca F.;Roberto M.;Pizzuti L.;Nuti M.;Marchetti P.
2019

Abstract

Background: The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection. Methods: Patients with stage IIIB-IV NSCLC receiving nivolumab at Sant'Andrea Hospital and Regina Elena National Cancer Institute from June 2016 to July 2017 were enrolled onto this study. Major clinicopathological parameters were retrieved and correlated with patients' survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision making process. Results: A total of 102 patients were included in this study. The median age was 69 years (range 44-85 years), 69 (68%) were male and 52% had ECOG PS 0. Loco-regional/distant lymph nodes were the most commonly involved site of metastasis (71%), followed by lung parenchyma (67%) and bone (26%). Overall survival (OS) in the whole patients' population was 83.6%, 63.2% and 46.9% at 3, 6 and 12 months, respectively; while progression-free survival (PFS) was 66.5%, 44.4% and 26.4% at 3, 6 and 12 months, respectively. At univariate analysis, age ≥ 69 years (P = 0.057), ECOG PS (P < 0.001), the presence of liver (P < 0.001), lung (P = 0.017) metastases, lymph nodes only involvement (P = 0.0145) were significantly associated with OS and ECOG PS (P < 0.001) and liver metastases (P < 0.001), retained statistical significance at multivariate analysis. A prognostic nomogram based on three variables (liver and lung metastases and ECOG PS) was built to assign survival probability at 3, 6, and 12 months after nivolumab treatment commencement. Conclusion: We developed a nomogram based on easily available and inexpensive clinical factors showing a good performance in predicting individual OS probability among NSCLC patients treated with nivolumab. This prognostic device could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enrollment onto clinical trials.
Immunotherapy; lung cancer; Nivolumab; Nomogram; prognostic factors
01 Pubblicazione su rivista::01a Articolo in rivista
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab / Botticelli, A.; Salati, M.; Di Pietro, F. R.; Strigari, L.; Cerbelli, B.; Zizzari, I. G.; Giusti, R.; Mazzotta, M.; Mazzuca, F.; Roberto, M.; Vici, P.; Pizzuti, L.; Nuti, M.; Marchetti, P.. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 17:1(2019), p. 99. [10.1186/s12967-019-1847-x]
File allegati a questo prodotto
File Dimensione Formato  
Botticelli_Predict-survival.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 950.38 kB
Formato Adobe PDF
950.38 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1306849
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 33
social impact